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A growing body of evidence indicates that office blood 
pressure (OBP) measurement alone, as performed by the 
physician, is not sufficient to determine a patient’s true 
blood pressure (BP) value. Although home blood pressure 
(HBP) measurement or ambulatory blood pressure 
monitoring (ABPM) may provide us with a better estimate 
of a patient’s BP, this may also cause problems if these 
two types of measurements lead to different treatment 
conclusions.
Most physicians are familiar with the discrepancy called 
white coat hypertension (WCH), which is defined as an 
elevated OBP value in the face of a normal BP outside 
the office, as determined by either ABPM or HBP. Since 
several studies have already shown that both ABPM and 
HBP correlate better with target organ damage than OBP, 
one may be inclined to think that WCH is rather harmless. 
However, some studies that evaluated the long-term 
effect of WCH on cardiovascular prognosis showed that 
subjects with WCH had an increased risk compared with 
normotensives, but a lower risk than those with sustained 
hypertension.1 These data indicate that OBP values should 
not be completely ignored.
Much less is known about the second discrepancy and, in 
fact, the opposite of WCH, namely masked hypertension 
(MH). Although many physicians are unfamiliar with MH, 
it is not a rare phenomenon as its prevalence ranges from 
8 to 33% among different populations.2,3 Some studies 
even found higher numbers of masked hypertensives 
when compared with white coat hypertensive subjects. 
However, it is difficult to determine the real prevalence of 
MH from the present literature as studies about MH vary 
widely in definitions, equipment used, populations and 
measurement procedures. This also holds true for the paper 
by Aksoy et al.4 in the present issue of the Journal. In this 
paper the authors dealt with the prevalence of MH among 
57 seemingly well-controlled, treated hypertensive patients 
and 31 untreated normotensive subjects. They found that 
MH occurred frequently in the hypertensives but not 
in the normotensives, although in some normotensive 
subjects there was a clear difference between OBP and 
HBP. However, the OBP procedure, as performed by 
Aksoy and co-workers, is rather unusual. The time before 
the first duplicated measurement was taken and the time 
between the other duplicated measurements amounted 
to ten minutes. When such a long time elapses before 
measurements are taken, the white coat effect will become 
smaller.5 Consequently, when patients are sitting longer in 
a chair before the OBP is taken, they will obtain a lower 
OBP value as compared with their HBP. 
Another reason why we still do not know much about 
MH is related to the large population differences 
(normotensives, hypertensives, younger subjects, elderly, 
treated and untreated subjects) among studies that have 
investigated MH. The study by Aksoy and co-workers 
shows that there were more patients declared to have 
masked hypertension in the hypertensive group than 
in the normotensive group. This may be attributed to at 
least three factors. Firstly, these patients have BP values 
that are closer to the upper limits of the definition of MH 
than normotensive patients. This means that a minor 
discrepancy between OBP and HBP would more easily 
lead to a classification of MH in hypertensive patients than 
in normotensive individuals. Secondly, the hypertensive 
patients were on antihypertensive drugs that they may have 
taken in the morning. HBP was performed in the early 
morning, at the ‘trough’ moment of the antihypertensive 
activity of the medication. OBP was regularly performed 
in a range of two to eight hours after drug intake so that 
it might already have had its influence on the BP. Thirdly, 
the percentage of men in the studies differs between 
both groups (47% in the group with treated hypertensives 
and 71% in the group with healthy volunteers). Indeed, 
some studies have shown that the prevalence of MH was 
higher among females than among males; however, other 
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studies found the opposite. Nevertheless, because of these 
differences in gender percentages between the two groups 
one should be careful when drawing conclusions from 
between-group comparisons. 
In most studies OBP was performed with a mercury 
sphygmomanometer, which is highly susceptible to 
observer bias, while HBP was commonly performed with 
an automatic oscillometric device. Observer bias reduces 
reliability of the obtained BP values while employment 
of different measurement devices further complicates 
comparisons between OBP and HBP. Therefore, Aksoy 
and co-workers did do well to perform all measurements 
with the same device: the Omron 705CP automatic 
device. However, for validation of the BP device used, 
the European Society of Hypertension (ESH) and the 
British Hypertension Society (BHS) allowed inaccuracy 
to 5 mmHg.6 This inaccuracy of the device should have 
been taken into account for analysis. Therefore, it is worth 
recommending the use of a ‘grey zone’ and allowing, for 
example, for 10 mmHg systolic and 6 mmHg diastolic 
BP differences between the OBP and SBP values. In that 
case MH would be defined as an HBP value that is at least 
10 mmHg systolic and 6 mmHg diastolic higher than the 
OBP value.
Overall knowledge of MH would significantly improve if all 
studies followed the same guidelines for BP measurement 
procedures and used the same validated oscillometric 
measurement device for both OBP and HBP. This would 
prevent observer bias and facilitate comparison between 
the procedures. 
The overall accepted definition of MH is the one 
recommended by the ESH7 (an OBP value <140/90 mmHg 
and an HBP value ≥135 mmHg systolic and/or 85 mmHg 
diastolic). Aksoy and co-workers also determined MH 
according to the ESH definition. They used the first of the 
duplicated office measurements as the OBP value, which 
led to more patients above the OBP limit (this decreases 
the MH prevalence) and naturally more patients had BP 
values above the HBP limit as the threshold decreased 
from 140/90 mmHg to 135/85 mmHg (this increases 
the MH prevalence). Together, this resulted in a higher 
MH prevalence than the previous definition (37 vs 28%). 
Although the ESH definition is commonly accepted, it 
is remarkable that patients can be classified as masked 
hypertensives when they obtain similar OBP and HBP 
values (e.g. 138/86 mmHg). This may be a reason to 
revise the ESH definitions, also because they assume 
that a physician will perform the OBP with a mercury 
sphygmomanometer and the HBP is assessed with an 
automatic oscillometric device. Since Aksoy and co-workers 
used the same oscillometric device for OBP and HBP, 
differences in BP values could not result from the device. 
Therefore, their first definition of MH seems to be the 
most appropriate one. 
The explanation for MH has been sought in factors that 
increase daytime ambulatory blood pressure such as 
physical activity, stressful conditions, tobacco and coffee,8,9 
alcohol,10 sedentary habits11 or greater reactivity to daily 
life stressors.12 However, MH could, of course, also be 
due to an exceptionally low OBP in the face of increased 
HBP or ABPM values. Low OBP values can be due to a 
postprandial dip or previous antihypertensive drug intake. 
Therefore, when patients take antihypertensive treatment 
it is absolutely essential to instruct patients carefully on 
how to take their drugs and verify, at each visit when 
OBP is performed, if and how their treatment was taken. 
Despite all speculations, the true identity of MH has not 
yet been revealed as the reproducibility of MH has not been 
investigated until now.
Since ABPM and HBP are better risk predictors than 
OBP,13-19 patients with MH, both treated and untreated, 
exhibit a cardiovascular risk similar to that of sustained 
hypertensive patients. When subjects have MH and their 
treatment is based on OBP results, these patients will not 
receive the treatment they should. For this reason it would 
be desirable if all patients performed HBP in addition 
to OBP. However, for practical reasons it is impossible 
to let all patients perform HBP. Therefore, HBP should 
be recommended, in particular, for patients with high 
cardiovascular risk or with symptoms possibly related to 
their BP level, or when there is a discrepancy between 
BP values and degree of target organ damage. Eventually, 
an additional ABPM could be performed to determine 
the most appropriate treatment if a discrepancy is found 
between OBP and HBP values.
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